SG11202009194XA - Cd4 muteins and methods of using the same - Google Patents

Cd4 muteins and methods of using the same

Info

Publication number
SG11202009194XA
SG11202009194XA SG11202009194XA SG11202009194XA SG11202009194XA SG 11202009194X A SG11202009194X A SG 11202009194XA SG 11202009194X A SG11202009194X A SG 11202009194XA SG 11202009194X A SG11202009194X A SG 11202009194XA SG 11202009194X A SG11202009194X A SG 11202009194XA
Authority
SG
Singapore
Prior art keywords
muteins
methods
same
Prior art date
Application number
SG11202009194XA
Inventor
Michael Farzan
Matthew Gardner
Ina Fetzer
Michael Alpert
Charles Bailey
Original Assignee
Scripps Research Inst
Emmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Emmune Inc filed Critical Scripps Research Inst
Publication of SG11202009194XA publication Critical patent/SG11202009194XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202009194XA 2018-03-21 2019-03-21 Cd4 muteins and methods of using the same SG11202009194XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862645903P 2018-03-21 2018-03-21
PCT/US2019/023422 WO2019183387A1 (en) 2018-03-21 2019-03-21 Cd4 muteins and methods of using the same

Publications (1)

Publication Number Publication Date
SG11202009194XA true SG11202009194XA (en) 2020-10-29

Family

ID=67986365

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009194XA SG11202009194XA (en) 2018-03-21 2019-03-21 Cd4 muteins and methods of using the same

Country Status (13)

Country Link
US (1) US20230159616A1 (en)
EP (1) EP3768293A4 (en)
JP (1) JP2024041907A (en)
KR (1) KR20200144549A (en)
CN (1) CN112188897A (en)
AU (1) AU2019240319A1 (en)
BR (1) BR112020019107A2 (en)
CA (1) CA3094691A1 (en)
EA (1) EA202092229A1 (en)
IL (1) IL277458A (en)
SG (1) SG11202009194XA (en)
WO (1) WO2019183387A1 (en)
ZA (1) ZA202006480B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0538371A4 (en) * 1990-07-11 1993-08-04 Smithkline Beecham Corporation Streptomyces vectors for production of heterologous proteins
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
CN105209057B (en) * 2013-03-15 2020-03-27 美国卫生和人力服务部 Stable human single CD4 domain and fusion protein
US10626161B2 (en) * 2015-04-28 2020-04-21 The Scripps Research Institute Methods and compositions for protection against lentiviral infections

Also Published As

Publication number Publication date
EP3768293A4 (en) 2022-07-06
KR20200144549A (en) 2020-12-29
WO2019183387A1 (en) 2019-09-26
EA202092229A1 (en) 2021-07-05
JP2021518171A (en) 2021-08-02
EP3768293A1 (en) 2021-01-27
BR112020019107A2 (en) 2020-12-29
IL277458A (en) 2020-11-30
CA3094691A1 (en) 2019-09-26
US20230159616A1 (en) 2023-05-25
CN112188897A (en) 2021-01-05
JP2024041907A (en) 2024-03-27
ZA202006480B (en) 2022-01-26
AU2019240319A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
IL271025A (en) Multibiotic agents and methods of using the same
IL271751A (en) Novel t cell receptors and immune therapy using the same
EP3245232A4 (en) Heterodimeric cas9 and methods of use thereof
IL274844A (en) Il-2 muteins and uses thereof
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
EP3724188C0 (en) Progranulin modulators and methods of using the same
GB2591554B (en) Composiitons and methods and uses relating thereto
EP3509612A4 (en) Cxcr4 antagonists and methods of use
ZA202100092B (en) Modified cas9 protein and use thereof
IL283782A (en) Anellosomes and methods of use
GB201820088D0 (en) Opitical devices and methods
IL281339A (en) Antigen-specific t lymphocytes and methods of making and using the same
IL263349A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
IL276979A (en) Macro-encapsulated therapeutic cells, devices, and methods of using the same
IL280369A (en) New myokines and uses thereof
IL269817A (en) Macro-encapsulated therapeutic cells and methods of using the same
ZA202006480B (en) Cd4 muteins and methods of using the same
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
IL282671A (en) Therapeutic methods and compositions
GB201821333D0 (en) Cutting elements and methods of making and using the same
GB201806133D0 (en) Methods and medical uses
GB201818904D0 (en) New formulations and methods
GB201812776D0 (en) New methods and uses
GB201816605D0 (en) New formulations and uses thereof
GB201802743D0 (en) Medicament and use thereof